Search research articles
Contact Us
Filters
Showing results (101-110 of 139) with videos related to
Page
of 14
Sort By:
Investigational New Drugs
|
July 14, 2007
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors
Jérôme Alexandre, Carmen Kahatt, Frédérique Bertheault-Cvitkovic, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2019
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
Sara I Pai, Sandrine Faivre, Lisa Licitra, et al.
Investigational New Drugs
|
May 10, 2006
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
Werner Hilgers, Sandrine Faivre, Stéphanie Chieze, et al.
Cancer
|
March 15, 2012
Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection
Gabriel G Malouf, Laurence Brugières, Marie-Cécile Le Deley, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 10, 2019
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Sandrine Faivre, Armando Santoro, Robin K Kelley, et al.
JCO Precision Oncology
|
February 14, 2024
Activity of Tepotinib in Hepatocellular Carcinoma With High-Level <i>MET</i> Amplification: Preclinical and Clinical Evidence
Shukui Qin, Hongming Pan, Jean Frédéric Blanc, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 9, 2010
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
Christophe Le Tourneau, Sandrine Faivre, Valérie Laurence, et al.
Molecular Cancer Therapeutics
|
April 22, 2010
Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells
Maria Serova, Lucile Astorgues-Xerri, Ivan Bieche, et al.
British Journal of Cancer
|
November 22, 2017
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response
Angela Lamarca, Jorge Barriuso, Matthew Kulke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 22, 2014
OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis
Lucile Astorgues-Xerri, Maria E Riveiro, Annemilaï Tijeras-Raballand, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 139) with videos related to
Sort By:
Page
of 14
Investigational New Drugs
|
July 14, 2007
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors
Jérôme Alexandre, Carmen Kahatt, Frédérique Bertheault-Cvitkovic, et al.
Journal for Immunotherapy of Cancer
|
April 5, 2019
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)
Sara I Pai, Sandrine Faivre, Lisa Licitra, et al.
Investigational New Drugs
|
May 10, 2006
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
Werner Hilgers, Sandrine Faivre, Stéphanie Chieze, et al.
Cancer
|
March 15, 2012
Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection
Gabriel G Malouf, Laurence Brugières, Marie-Cécile Le Deley, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 10, 2019
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Sandrine Faivre, Armando Santoro, Robin K Kelley, et al.
JCO Precision Oncology
|
February 14, 2024
Activity of Tepotinib in Hepatocellular Carcinoma With High-Level <i>MET</i> Amplification: Preclinical and Clinical Evidence
Shukui Qin, Hongming Pan, Jean Frédéric Blanc, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 9, 2010
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
Christophe Le Tourneau, Sandrine Faivre, Valérie Laurence, et al.
Molecular Cancer Therapeutics
|
April 22, 2010
Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells
Maria Serova, Lucile Astorgues-Xerri, Ivan Bieche, et al.
British Journal of Cancer
|
November 22, 2017
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response
Angela Lamarca, Jorge Barriuso, Matthew Kulke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 22, 2014
OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis
Lucile Astorgues-Xerri, Maria E Riveiro, Annemilaï Tijeras-Raballand, et al.
Page
of 14